Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.

E M McDermott, R J Powell

Clinical Immunology Unit, University Hospital, Nottingham, United Kingdom.

OBJECTIVE: To investigate the incidence of ovarian failure after pulse cyclophosphamide treatment in systemic lupus erythematosus (SLE) and to compare this with two control groups: SLE patients treated with azathioprine, and a healthy age matched population. METHODS: All women patients with SLE treated with pulse cyclophosphamide in our department were identified and questioned concerning menstrual history. All the hospital notes were reviewed and details recorded on dose of cyclophosphamide, duration of treatment, side effects and lowest pretreatment neutrophil and leucocyte counts during the course of treatment. Disease controls were recruited from our department and healthy controls from the local family health services authority (FHSA) register. RESULTS: Incidence of ovarian failure in the premenopausal cyclophosphamide treated group was 54% and the incidence of premature menopause (occurring before age 40 years) was 41%. Increasing age at start of treatment showed a linear trend with incidence of ovarian failure (p = 0.01). Using logistic regression, increasing duration of treatment was related to incidence of ovarian failure (p = 0.047 in those treated age 35 years or younger). An association between the lowest neutrophil count throughout the treatment period, when taken immediately before each planned cyclophosphamide pulse, and the incidence of ovarian failure was also demonstrated (p = 0.04 in those treated before age 40 years). CONCLUSION: Ovarian failure--in particular, premature failure after treatment with pulse cyclophosphamide--is common. Factors associated with increased risk include greater age at start of treatment, longer period of treatment, and greater degree of marrow suppression as assessed by the neutrophil count immediately before each planned cyclophosphamide pulse.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Medeiros, P., Febronio, M., Bonfa, E, Borba, E., Takiuti, A., Silva, C. (2009). Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus 18: 38-43 [Abstract]  
• Gonzalez, L A, McGwin, G Jr, Duran, S, Pons-Estel, G J, Apte, M, Vila, L M, Reveille, J D, Alarcon, G S, for the LUMINA Study Group, (2008). Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII). Ann Rheum Dis 67: 1170-1173 [Abstract] [Full Text]  
• Silva, C.A.A., Hilario, M.O., Febronio, M.V., Oliveira, S.K., Terreri, M.T., Sacchetti, S.B., Sztajnbok, F.R., Marini, R., Quintero, M.V., Bica, B.E., Pereira, R.M., Bonfa, E., Ferriani, V.P., Robazzi, T.C., Magalhaes, C.S. (2007). Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study. Lupus 16: 531-536 [Abstract]  
• Brunner, H I, Bishnoi, A, Barron, A C, Houk, L J, Ware, A, Farhey, Y, Mongey, A B, Strife, C F, Graham, T B, Passo, M H (2006). Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 15: 198-206 [Abstract]  
• Raptopoulou, A., Sidiropoulos, P., Boumpas, D. T (2004). Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. Lupus 13: 887-890  
• Katsifis, G E, Tzioufas, A G (2004). Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 13: 673-678 [Abstract]  
• Park, M-C, Park, Y-B, Jung, S Y, Chung, I H, Choi, K H, Lee, S-K (2004). Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 13: 569-574 [Abstract]  
• Petri, M (2004). Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 13: 366-371 [Abstract]  
• Katsifis, G. E., Tzioufas, A. G., Vlachoyiannopoulos, P. G., Voulgarelis, M., Moutsopoulos, H. M., Ioannidis, J. P. A. (2002). Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford) 41: 780-786 [Abstract] [Full Text]  
• Blumenfeld, Z, Shapiro, D, Shteinberg, M, Avivi, I, Nahir, M (2000). Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 9: 401-405 [Abstract]  
• Duddridge, M, Powell, R J (1997). Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56: 690-692 [Abstract] [Full Text]  
• Werth, V. P. (1997). Pulse Intravenous Cyclophosphamide for Treatment of Autoimmune Blistering Disease: Is There an Advantage Over Oral Routes?. Arch Dermatol 133: 229-230 [Abstract]